Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses

  • Nat Commun. 2025 Jul 1;16(1):5831. doi: 10.1038/s41467-025-60232-3.
Arne Matthys  1  2 Jan Felix  2  3 Joao Paulo Portela Catani  1  2 Kenny Roose  1  2 Wim Nerinckx  1  2 Benthe Van Buyten  1  2 Daria Fijalkowska  1  2 Nico Callewaert  1  2 Savvas N Savvides  2  3 Xavier Saelens  4  5
Affiliations
  • 1. VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.
  • 2. Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
  • 3. Unit for Structural Biology, VIB-UGent Center for Inflammation Research, Ghent, Belgium.
  • 4. VIB Center for Medical Biotechnology, VIB, Ghent, Belgium. [email protected].
  • 5. Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium. [email protected].
Abstract

Influenza B viruses are antigenically diverse and contribute significantly to the annual influenza burden. Here we report influenza B virus neutralizing single-domain antibodies that target highly conserved regions of the hemagglutinin and neuraminidase. Structural studies by single particle electron cryo-microscopy (cryo-EM) revealed that one of these single-domain antibodies prevents the conformational transition of the viral hemagglutinin to the post-fusion state by targeting a quaternary epitope spanning two protomers in the hemagglutinin-stem region. A second single-domain antibody broadly inhibits influenza B neuraminidase activity, including an oseltamivir-resistant neuraminidase, and its complex with neuraminidase elucidated by single particle cryo-EM established that it binds to residues in the neuraminidase catalytic site. Head-to-tail fusions of these single-domain antibodies led to bispecific Binders that further improved the neutralization breadth and potency against influenza B viruses. These single-domain antibodies, fused to a human IgG1-Fc domain, fully protected female mice against an otherwise lethal influenza B virus challenge. Our findings underscore the potential of engineered single-domain antibodies to help control influenza B virus infections.

Products